We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Kanabo Group plc (KNB) ORD GBP0.025

Sell:0.90p Buy:1.10p 0 Change: No change
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.90p
Buy:1.10p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.90p
Buy:1.10p
Change: No change
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Company’s principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.

Contact details

Address:
Churchill House, 137-139 Brent Street
LONDON
NW4 4DJ
United Kingdom
Telephone:
+ (0)
Website:
https://www.kanabogroup.com/investors/

Important dates

Future events
There are no future events available.
Past events
Interim results 30 September 2024 30/09/24
AGM 27 June 2024 27/06/24
Final results 30 April 2024 30/04/24
Annual report 30 April 2024 30/04/24

General stock information

EPIC:
KNB
ISIN:
GB00BYQCS703
Market cap:
£6.32 million
Shares in issue:
632.43 million
Sector:
Nonequity Investment Instruments
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Avihu Tamir
    Chief Executive Officer, Executive Director
  • Assaf Vardimon
    Chief Financial Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.